Novartis Ag (NVSEF) Cost of Revenue (2009 - 2025)

Novartis Ag has disclosed Cost of Revenue across 15 years of filings, most recently posting $3.3 billion for Q2 2025.

• Cost of Revenue for Q2 2025 came in at $3.3 billion, up 4.7% year-over-year; the trailing twelve-month figure through Jun 2025 was $19.1 billion (up 44.96% YoY), and the FY2025 annual result was $13.7 billion, up 6.8% from the prior year.
• Cost of Revenue came in at $3.3 billion for Q2 2025 at Novartis Ag, down from $6.3 billion in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $6.3 billion in Q4 2023 to a low of $236.0 million in Q3 2022.
• The 5-year median for Cost of Revenue is $1.7 billion (2023), against an average of $2.3 billion.
• Peak annual rise in Cost of Revenue reached 2403.16% in 2023, while the deepest fall reached 10.9% in 2023.
• Novartis Ag's Cost of Revenue stood at $238.0 million in 2021, then climbed by 6.3% to $253.0 million in 2022, then soared by 2403.16% to $6.3 billion in 2023, then decreased by 1.01% to $6.3 billion in 2024, then tumbled by 47.01% to $3.3 billion in 2025.
• The last three Cost of Revenue figures came in at $3.3 billion (Q2 2025), $6.3 billion (Q4 2024), and $3.2 billion (Q2 2024), per Business Quant data.